Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 9/20 | 1.00 |
| ▸ | MAP2K1 | Q02750 | 9/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | APP | P05067 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6324928 | 0.90 | RAF1 (0.82) | RAF1MAP2K1KDM4EALDH1A1APP | |
| SCHEMBL6327100 | 0.90 | RAF1 (0.82) | RAF1MAP2K1KDM4EALDH1A1APP | |
| SCHEMBL6324574 | 0.89 | RAF1 (0.80) | RAF1MAP2K1KDM4EALDH1A1TDP1 | |
| SCHEMBL6327310 | 0.89 | RAF1 (0.80) | RAF1MAP2K1KDM4EALDH1A1APP | |
| SCHEMBL6326868 | 0.88 | RAF1 (0.79) | RAF1MAP2K1KDM4EALDH1A1APP | |
| SCHEMBL6324891 | 0.87 | RAF1 (0.80) | RAF1MAP2K1KDM4EALDH1A1APP | |
| SCHEMBL6327025 | 0.87 | RAF1 (0.76) | RAF1MAP2K1KDM4EALDH1A1APP | |
| SCHEMBL6322178 | 0.87 | RAF1 (0.76) | RAF1MAP2K1KDM4EALDH1A1APP | |
| SCHEMBL6616512 | 0.85 | RAF1 (0.74) | RAF1MAP2K1KDM4EALDH1A1APP | |
| SCHEMBL6324552 | 0.85 | RAF1 (0.73) | RAF1MAP2K1KDM4EALDH1A1APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | claimed |
| WO-2025027223-A1 | DYRK2 INHIBITORS FOR TREATING TUMOURS WITH THE HYPERACTIVE MAPK/ERK PATHWAY | Universidad de Córdoba (ES) | 2025-02-06 | — | — | WO | claimed |
| US-20240390373-A1 | RAF KINASE INHIBITORS FOR TREATING TUMORS HARBORING GENE FUSIONS | DAY ONE BIOPHARMACEUTICALS, INC. | 2024-11-28 | — | — | US | claimed |
| WO-2024102187-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | PINETREE THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | WO | claimed |
| WO-2024011307-A1 | PYRAZOLO[3,4-D]PYRIMIDIN-6-YL-SULFONAMIDE DERIVATIVES FOR THE INHIBITION OF SGK-1 AND TREATMENT OF CANCER | THRYV THERAPEUTICS INC. (CA) | 2024-01-18 | — | — | WO | claimed |
| WO-2026044398-A1 | SALTS OF 5-CHLORO-2-FLUORO-N-(2-FLUORO-4-(3-METHYL-4-[(1-METHYLPIPERIDIN-4-YL)OXY]-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL)PHENYL)BENZENE SULFONAMIDE AND CRYSTALLINE FORMS THEREOF | THRYV THERAPEUTICS INC. (CA) | 2026-03-05 | — | — | WO | disclosed |
| EP-4659812-A1 | DETECTION METHODS AND COMBINATION THERAPIES OF CELLS WITH EXTRACELLULAR RAS EXPRESSION | Bumm, Thomas (DE) | 2025-12-10 | — | — | EP | disclosed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| US-20250281607-A1 | MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER | TORAY INDUSTRIES, INC. (JP) | 2025-09-11 | — | — | US | disclosed |
| WO-2025027223-A1 | DYRK2 INHIBITORS FOR TREATING TUMOURS WITH THE HYPERACTIVE MAPK/ERK PATHWAY | Universidad de Córdoba (ES) | 2025-02-06 | — | — | WO | disclosed |
| US-20240390373-A1 | RAF KINASE INHIBITORS FOR TREATING TUMORS HARBORING GENE FUSIONS | DAY ONE BIOPHARMACEUTICALS, INC. | 2024-11-28 | — | — | US | disclosed |
| CN-111799148-B | Ion detector | 浜松光子学株式会社 | 2024-10-29 | — | — | CN | disclosed |
| US-11242344-B2 | (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof | GENENTECH, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20210309660-A1 | (4-HYDROXYPYRROLIDIN-2-YL)-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2021-10-07 | — | — | US | disclosed |
| WO-2019183523-A1 | HETERO-BIFUNCTIONAL DEGRADER COMPOUNDS AND THEIR USE AS MODULATORS OF TARGETED UBIQUINATION (VHL) | GENENTECH, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| EP-1845985-A2 | AMINE DERIVATIVE CONTAINING COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS RELATED TO THE ETIOLOGY OF CANCER | NexusPharma Inc. (US) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006084116-A2 | AMINE DERIVATIVE CONTAINING COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS RELATED TO THE ETIOLOGY OF CANCER | NEXUSPHARMA INC. (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20050228017-A1 | Novel anticancer compounds | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE | 2005-10-13 | — | — | US | disclosed |
| EP-1442018-A1 | NOVEL ANTICANCER COMPOUNDS | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003037865-A1 | NOVEL ANTICANCER COMPOUNDS | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228017-A1 | Novel anticancer compounds | TP53, ABCG2, MCL1 | RAF1 660/4885MAP2K1 4672/4885KDM4E 2416/4885 |
| US-20210309660-A1 | (4-HYDROXYPYRROLIDIN-2-YL)-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | VHL, MDM2, CUL2 | RAF1 2275/4885MAP2K1 1949/4885KDM4E 731/4885 |
| US-11242344-B2 | (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof | VHL, MDM2, CUL2 | RAF1 2275/4885MAP2K1 1949/4885KDM4E 731/4885 |
| US-20240390373-A1 | RAF KINASE INHIBITORS FOR TREATING TUMORS HARBORING GENE FUSIONS | BRAF, ARAF, KRAS | RAF1 5/4885MAP2K1 986/4885KDM4E 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.